Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CYT 103 - Cytovia Therapeutics

Next Previous
Drug Profile

CYT 103 - Cytovia Therapeutics

Alternative Names: CYT-103

Latest Information Update: 13 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytogen Corporation
  • Class Antineoplastics; Bispecific antibodies; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Liver cancer

Most Recent Events

  • 14 Nov 2022 Preclinical trials in Liver cancer in USA (Parenteral), before November 2022 (Cytovia Therapeutics pipeline, November 2022)
  • 14 Nov 2022 Cytovia therapeutics announces Plans to initiate Investigator Initiated trial for Liver cancer in China in 2023 (Cytovia Therapeutics pipeline, November 2022)
  • 18 Nov 2021 Cytovia Therapeutics expanded its strategic research and development collaboration with Cellectis regarding TALEN® gene-edited induced pluripotent stem cells (iPSCs)-derived natural killer (NK) and chimeric antigen receptor (CAR)-NK cells

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top